152 related articles for article (PubMed ID: 36159517)
1. Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report.
Xuan TT; Li GY; Meng SB; Wang ZM; Qu LL
World J Clin Cases; 2022 Aug; 10(23):8284-8290. PubMed ID: 36159517
[TBL] [Abstract][Full Text] [Related]
2. Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
Bronte G; Delmonte A; Burgio MA; Verlicchi A; Puccetti M; Bravaccini S; Cravero P; Tumedei MM; Diano D; Rossi G; Ulivi P; Martinelli G; Crinò L
Lung Cancer; 2020 Apr; 142():47-50. PubMed ID: 32088605
[TBL] [Abstract][Full Text] [Related]
3. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Alley EW; Lopez J; Santoro A; Morosky A; Saraf S; Piperdi B; van Brummelen E
Lancet Oncol; 2017 May; 18(5):623-630. PubMed ID: 28291584
[TBL] [Abstract][Full Text] [Related]
4. Acquired resistance to immunotherapy characterized by bloody pleural effusion and biomarker exploration: a report of 2 cases.
Zeng X; Zhang Y; Zhang Y; Lei Y; Gu K
Ann Palliat Med; 2022 Feb; 11(2):843-849. PubMed ID: 35249354
[TBL] [Abstract][Full Text] [Related]
5. Management of Advanced Pleural Mesothelioma-At the Crossroads.
Nowak AK; Jackson A; Sidhu C
JCO Oncol Pract; 2022 Feb; 18(2):116-124. PubMed ID: 34491782
[TBL] [Abstract][Full Text] [Related]
6. A Complete Response to Pembrolizumab in Malignant Peritoneal Mesothelioma: A Case Report.
Bairos Menezes M; Pedroso de Lima R; Dunões I; Inácio M; Dinis R
Cureus; 2024 Jan; 16(1):e52716. PubMed ID: 38384604
[TBL] [Abstract][Full Text] [Related]
7. Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma).
Shalata W; Iraqi M; Bhattacharya B; Fuchs V; Roisman LC; Cohen AY; Massalha I; Yakobson A; Prasad M; Elkabets M; Porgador A; Peled N
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298855
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
9. Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy.
Hearon BF; Redelman KN; Elhomsy GC; Moore DF
Case Rep Oncol; 2020; 13(3):1483-1489. PubMed ID: 33442373
[TBL] [Abstract][Full Text] [Related]
10. [Advances in Immunotherapy for Malignant Pleural Mesothelioma].
Chi Y; Liu Y; Zhao J
Zhongguo Fei Ai Za Zhi; 2022 Apr; 25(4):259-265. PubMed ID: 35477190
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies in malignant pleural mesothelioma.
Cinausero M; Rihawi K; Cortiula F; Follador A; Fasola G; Ardizzoni A
Crit Rev Oncol Hematol; 2019 Dec; 144():102815. PubMed ID: 31670225
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with
Malignant Pleural Mesothelioma].
Zeng X; Jiang Z; Duan J
Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
[TBL] [Abstract][Full Text] [Related]
13. Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
Di Noia V; Vita E; Ferrara M; Strippoli A; Basso M; Schinzari G; Cassano A; Bria E; Barone C; D'Argento E
Curr Treat Options Oncol; 2019 Feb; 20(3):23. PubMed ID: 30790063
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
15. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
[TBL] [Abstract][Full Text] [Related]
16. Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review.
Piao MN; Ma XT; Tankere P; Liam CK; Li JL; Wang JP
Ann Transl Med; 2022 Sep; 10(18):1030. PubMed ID: 36267791
[TBL] [Abstract][Full Text] [Related]
17. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
[TBL] [Abstract][Full Text] [Related]
18. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Popat S; Curioni-Fontecedro A; Dafni U; Shah R; O'Brien M; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Nadal E; Janthur WD; López Castro R; García Campelo R; Rusakiewicz S; Letovanec I; Polydoropoulou V; Roschitzki-Voser H; Ruepp B; Gasca-Ruchti A; Peters S; Stahel RA
Ann Oncol; 2020 Dec; 31(12):1734-1745. PubMed ID: 32976938
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]